Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79973.980.1671%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

BioCryst Pharmaceuticals Inc (BCRX) Stock Price, Quote, News & History

BCRXNASDAQ
Trade with Public
Trade with Public
$9.96
-0.13-1.29%
At close: Sep 4, 5:00 PM EST
$10.02
0.060.6%
After Hours: Sep 4, 6:47 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

BioCryst Pharma (BCRX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$10.00
Close
$9.96
Volume / Avg.
1.50M / 4.25M
Day Range
$9.90 - $10.10
52 Wk Range
6.00 - 11.22
Market Cap
$2.56B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
55
Short Interest
12.99%
Days to Cover
7.97

Recent BioCryst Pharmaceuticals, Inc. News

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.
Avi Kapoor

Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.
Avi Kapoor

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.
Avi Kapoor

Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.
Avi Kapoor

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
376.14M
Investing Cash Flow (TTM)
-448.71M
Financing Cash Flow (TTM)
124.63M
Free Cash Flow (TTM)
373.38M
Capital Expenditure (TTM)
-2.76M
Net Change in Cash (TTM)
52.05M

Analyst Trends and Forecast

2
May
2
Jun
1
1
Jul
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$2.99B
PE Ratio (TTM)
-
PE Ratio (FWD)
17.12
PEG Ratio (TTM)
-
PS Ratio (TTM)
2.51
PB Ratio (TTM)
-
Earnings Yield % (TTM)
-13.86%
Earnings Yield % (FWD)
5.84%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
6.33
Book Value / Share
-$1.78

Company Debt

Total Debt
$778.38M
LT Debt
$778.38M
LT Debt Issuance (TTM)
$400.00M
LT Debt Repayment (TTM)
-$232.14M
Total Cash
$154.97M
Debt to Equity
-
Issuance of Debt (TTM)
$167.87M
Repayment of Debt (TTM)
-$232.14M

Key Statistics

Open
$10.00
Close
$9.96
Volume / Avg.
1.50M / 4.25M
Day Range
$9.90 - $10.10
52 Wk Range
6.00 - 11.22
Market Cap
$2.56B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
55
Short Interest
12.99%
Days to Cover
7.97

About

Sector
Health Care
Industry
Biotechnology
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple sci...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy BioCryst Pharma (BCRX) stock?

A

You can purchase shares of BioCryst Pharma (NASDAQ:BCRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioCryst Pharma (BCRX) competitors?

Q

What is the forecast, or price target, for BioCryst Pharma (BCRX) stock?

A

BioCryst Pharma has a consensus price target of $20.79.

Q

What is the current price for BioCryst Pharma (BCRX)?

A

The stock price for BioCryst Pharma (NASDAQ: BCRX) is $10.02 last updated September 4, 2026 at 6:47 PM EDT.

Q

Does BioCryst Pharma (BCRX) pay a dividend?

A

There are no upcoming dividends for BioCryst Pharma.

Q

When is BioCryst Pharma (NASDAQ:BCRX) reporting earnings?

A

BioCryst Pharma does not have any upcoming earnings scheduled.

Q

Is BioCryst Pharma (BCRX) going to split?

A

There is no upcoming split for BioCryst Pharma.

Q

What sector and industry does BioCryst Pharma (BCRX) operate in?

A

BioCryst Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved